Thermo Fisher Scientific — Equity Research & Investment Analysis

Team: Robin Larsson (Lead Analyst), Rasmus Bogren, Valeria Vitale

Thermo Fisher Scientific was selected as a third investment candidate for the university investment club. The analysis focused on the healthcare and life sciences sector — a defensively positioned, structurally growing market with high barriers to entry.

Company Overview

Thermo Fisher Scientific is an American life sciences company founded in 2006 through the merger of Thermo Electron and Fisher Scientific (with roots dating back to 1956). Headquartered in Waltham, Massachusetts, it is the world leader in serving science with annual revenue of ~$40B, 130,000+ employees (up from 75,000 in 2019 — almost doubled through acquisitions), and the same CEO, Marc N. Casper, since 2009.

The company consists of nine operating brands: Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, PPD, Ion Torrent, and Gibco.

Business Segments and Geography

Revenue breakdown by segment: - Life Sciences Solutions: 37.0% - Laboratory Products & Services: 35.2% - Analytical Instruments: 14.4% - Specialty Diagnostics: 13.4%

Revenue breakdown by geography: - United States: 48.2% - China: 8.8% - Rest of world: 43.0%

Market Analysis

The company operates at the intersection of two fast-growing markets: - Global healthcare market: projected to reach $665.37B by 2028; US healthcare spending estimated to double from $4T (2020) to $8.3T by 2040 - Clinical diagnostics market: $70B (2021) → $99B by 2027, growing at 6.1% CAGR, driven by infectious and chronic disease incidence and automated platform adoption

Company Analysis

• Mission: "enabling customers to make the world healthier, cleaner and safer"
• Growth strategy rests on three pillars: developing high-impact innovative products, leveraging scale in high-growth and emerging markets, and delivering a unique value proposition
• Aggressive acquisition model: formed by merger, then made ~40 further acquisitions — including PeproTech ($1.85B, Dec 2021), PPD ($17.4B clinical research organisation, Dec 2021), Mesa BioTech (Feb 2021), and Propel Labs cell sorting technology (Feb 2021)
• $3B share buyback programme authorised (Q3 2021)
• Committed to net-zero carbon emissions by 2050; 30% GHG reduction target by 2030
• Named on Forbes most female-friendly companies list; 100% LGBTQ+ workplace equality rating (HRC) for seventh consecutive year

Competitor Analysis

| Competitor | Revenue | Market Cap | Focus | |---|---|---|---| | Roche | $61.2B | $323.95B | Pharma + diagnostics | | Abbott | $43.1B | $212.2B | Diagnostics, medical devices | | Danaher | $29.5B | $180.3B | Life sciences, diagnostics, environmental | | Ingersoll Rand | $5.2B | $19.2B | Industrial flow & compression |

Thermo Fisher competes across all segments but differentiates through its breadth of portfolio (equipment, consumables, reagents, software) and acquisition-driven knowledge accumulation.

Financial Analysis

• Revenue CAGR of 12.64% since 2018 — stable, accelerating growth
• P/E ratio of 28 — in line with peers
• PEG ratio of 1.85 — more attractive than most competitors, indicating the company is growing faster than its valuation implies
• Low dividend payout (quarterly dividend of $0.26/share) with the majority of capital returned via share buybacks rather than dividends
• Strong net earnings and profit margins in line with the peer group; efficient asset management

Technical Analysis

• At time of analysis: stock trading below both the 50 and 200 SMA — a short-term bearish signal, but interpreted as a buying opportunity rather than a structural break
• RSI reaching oversold territory — a classic mean-reversion setup in a fundamentally strong company
• Year-to-date: down -18% (in line with broader market correction)
• Three-year performance: up +96%, outperforming both the S&P 500 and OMXS30 over the longer horizon
• The team interpreted the dip as a discount entry point into a high-quality compounder

Conclusion: STRONG BUY

Thermo Fisher combines defensively positioned, structurally growing markets with an acquisition-driven growth engine and strong financial fundamentals. The short-term technical weakness (below SMAs, oversold RSI) provided an attractive entry point into a company with a multi-decade track record of compounding shareholder value. The team's strong conviction was reflected in a STRONG BUY recommendation.